AI Article Synopsis
- The study examined the effects of sibutramine on 67 obese adolescents (24 boys, 43 girls) aged 12-18 over a 6-month period.
- After treatment, the average weight of patients decreased significantly from 91.6 kg to 81.9 kg, indicating an effective weight loss (P<.001).
- The common side effects reported included increased blood pressure and pulse, constipation, and dry mouth, suggesting that while sibutramine is effective, there are noteworthy safety considerations.
Article Abstract
A study on the treatment of obese adolescents with the use of sibutramine in private practice is presented. Patients consisted of 24 boys and 43 girls with obesity (body mass index [BMI]>85th percentile sex-specific BMI for age and sex) ranging from 12 to 18 years of age. Patients were given sibutramine 10 mg per day for 6 months. With the last observation carried forward adjustment, after 6 months of treatment, patients' average weight changed from 91.6+/-19.7 kg to 81.9+/-19.0 kg (P<.001), that is, 89.5+/-7.3% of initial weight. The most frequently reported adverse events included increased blood pressure and pulse rate (n=7), constipation (n=8), dry mouth (n=4), and constipation and dry mouth (n=3). Sibutramine may be considered effective for the treatment of obese adolescents, with a level of safety similar to that observed in adult patients.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1007/BF02849958 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Pharmacologic Treatment of Obesity in adults and its impact on comorbidities: 2024 Update and Position Statement of Specialists from the Brazilian Association for the Study of Obesity and Metabolic Syndrome (Abeso) and the Brazilian Society of Endocrinology and Metabolism (SBEM).
Arch Endocrinol Metab
December 2024
Centro de Obesidade Hospital Nove de Julho São PauloSP Brasil Centro de Obesidade, Hospital Nove de Julho, São Paulo, SP, Brasil.
Pharmacological treatment of obesity is passing through many changes in the last decades; different agents have been approved, and newer options are leaning towards higher efficacy and a more favourable safety profile; however, medications approved for a longer time are still available and useful for many patients. This document is an 2024 Update Position Statement of Specialists from the Brazilian Association for the Study of Obesity and Metabolic Syndrome (Abeso) and the Brazilian Society of Endocrinology and Metabolism (SBEM), with the aim of reviewing all the approved medications for the management of obesity in Brazil (sibutramine, orlistat, liraglutide, semaglutide and bupropion/naltrexone fixed dose), with the addition of tirzepatide, that is approved in other countries and likely approved soon in Brazil. The review is focused on efficacy, safety profile and the impact of drugs (based on existing studies) on different comorbidities.
View Article and Find Full Text PDFEvaluation of Anti-obesity Potential of Leaves.
Arch Razi Inst
April 2024
Department of Biotechnology, KAHER's Dr. Prabhakar Kore Basic Science Research Centre, Belagavi-590010, Karnataka, India.
Obesity has been an important health concern for over a decade, causing serious health issues worldwide. Treatments available for obesity include FDA-approved drugs such as Lorcaserin, Orlistat, Bupropion, combinations of Phentermine and Topiramate, and Sibutramine; however, these have adverse effects on health. To address the said issue, the current study was conducted to evaluate the anti-obesity potential of leaves.
View Article and Find Full Text PDFThe Effectiveness of Nonsurgical Interventions for Weight Loss Maintenance in Adults: An Updated, GRADE-Assessed Systematic Review and Meta-Analysis of Randomized Clinical Trials.
Nutr Rev
September 2024
Department of Nutrition, School of Public Health, Iran University of Medical Sciences, Tehran 1449614535, Iran.
Context: Today, there are many discussions about the best way to maintain weight and prevent weight regain after a period of weight loss.
Objectives: The aim of this study was to summarize, based on data from randomized clinical trials (RCTs), the impact of nonsurgical interventions for adults' weight loss maintenance.
Data Sources: The Medline (PubMed), Scopus, and Web of Science databases were reviewed during June 2023.
The history of anti-obesity pharmacotherapies is marked by disappointments, often entangled with societal pressure promoting weight loss and the conviction that excess body weight signifies a lack of willpower. However, categories of emerging pharmacotherapies generate hope to reduce obesity rates. This systematic review of phase 2 and phase 3 trials in adults with overweight/obesity investigates the effect of novel weight loss pharmacotherapies, compared to placebo/control or Food and Drug Administration-approved weight loss medication, through searching Medline, Embase, and ClinicalTrials.
View Article and Find Full Text PDFCharting New Territories in Obesity Management- Traditional Techniques to Tirzepatide.
Endocr Pract
September 2024
Department of Medicine, Karachi Medical and Dental College, Karachi, Pakistan.
Background: Obesity, a pervasive global health challenge affecting more than 2 billion people, requires comprehensive interventions. Traditional approaches, including lifestyle modification, and diverse drugs targeting a gastrointestinal hormone, including glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 (Liraglutide, Semaglutide, Exenatide, Albiglutide, Dulaglutide, Lixisenatide, Orlistat, Phentermine/Topiramate, Lorcaserin, Sibutramine, and Rimonabant) offer tailored strategies; yet their effectiveness is limited and some drugs were taken off the market. Moreover, various surgical modalities, such as Roux-en-Y Bypass surgery, sleeve gastrectomy, intragastric balloons, biliopancreatic diversion with duodenal switch, laparoscopic adjustable gastric band, and vagal nerve blockade can be considered but are associated with numerous side effects and require careful monitoring.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!